No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Biotage AB (publ), established in 1969 and based in Uppsala, Sweden, specializes in providing advanced separation technologies essential for fields such as organic and analytical chemistry, biomolecule research, and industrial scale-up applications. The company offers a comprehensive range of products, including solutions for organic and peptide synthesis, flash chromatography, evaporation, and work-up procedures, along with specialized systems, accessories, and various cartridges (normal, reversed, and specialty phase). Biotage also supplies solutions for plasmid and protein purification, encompassing antibody and tagged protein purification, automation systems, custom packing services, and diverse PhyTip columns. Additionally, they provide extensive sample preparation solutions tailored for clinical, bioanalytical, forensic, toxicology, doping control, environmental, and food and agriculture sectors, complemented by necessary consumables. Their offerings further include metal scavengers, reagents, and essential spare parts. Biotage serves a broad client base, including pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government agencies, academic institutions, and various clinical, forensic, and academic laboratories. With a significant global footprint, the company operates in 70 countries across the Americas, Europe, the Middle East, Africa, and Asia Pacific.
www.biotage.comNo one on the platform currently holds BIOT.ST.
No tracked institution reports a position in BIOT.ST as of their last filing.
No one on the platform has traded BIOT.ST yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.4% | 14.3% | 18.8% | — | — | — |
| Rev. Growth % | 10.4% | 13.3% | ||||
| Profit Margin % | 13.8% | 15.4% | 15.7% | |||
| Free Cash Flow Margin % | 11.9% | 17.4% | 16.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.1B | +8.2% | $4.25 | $3.54–$4.97 | — | 1 |
| 2027 | $2.3B | +9.1% | $4.83 | $4.20–$5.47 | — | 1 |
| 2028 | $3.5B | +56.6% | $7.50 | $6.52–$8.48 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-04-23 | $0.22 | $0.62 | +181.8% |
| 2025-02-19 | $1.72 | $1.98 | +15.1% |
| 2024-10-23 | $0.65 | $0.55 | -15.4% |
| 2024-07-16 | $0.42 | $0.60 | +42.9% |
| 2024-04-25 | $0.38 | $0.42 | +10.5% |
| 2024-02-15 | $1.13 | $1.64 | +45.1% |
| 2023-10-25 | $0.59 | $0.48 | -18.6% |
| 2023-07-17 | $0.77 | $0.49 | -36.4% |
| +0.87% |
| $11.2B |
| — |
| ELOS-B.STElos Medtech AB (publ) | $203.00 | +1.50% | $1.6B | — |
| INDEX.STInDex Pharmaceuticals Holding AB (publ) | $0.56 | +3.72% | $3.7B | — |
Source: Financial Modeling Prep · peers by sector/industry